Information on EC 3.4.24.86 - ADAM 17 endopeptidase and Organism(s) Homo sapiens and UniProt Accession P78536

for references in articles please use BRENDA:EC3.4.24.86
Word Map on EC 3.4.24.86
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
This record set is specific for:
Homo sapiens
UNIPROT: P78536


The taxonomic range for the selected organisms is: Homo sapiens

The enzyme appears in selected viruses and cellular organisms

EC NUMBER
COMMENTARY hide
3.4.24.86
-
RECOMMENDED NAME
GeneOntology No.
ADAM 17 endopeptidase
-
CAS REGISTRY NUMBER
COMMENTARY hide
151769-16-3
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
malfunction
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(EDANS)-ELAQAVRSSSRK-(DABCYL) + H2O
?
show the reaction diagram
-
TNF-alpha derived substrate
-
-
?
(EDANS)-EPLAQAVRSSSK-(DABCYL) + H2O
?
show the reaction diagram
-
TNF-alpha derived substrate
-
-
?
amphiregulin + H2O
?
show the reaction diagram
-
ADAM17, but not related ADAM10, is required for amphiregulin, TGF-alpha, and TNFR1 shedding
-
-
?
CD16 + H2O
?
show the reaction diagram
-
substrates CD16a and CD16b are IgG Fc receptors expressed by human natural killer cells and neutrophils, respectively. Substrates contain three separate cleavage sites in close proximity at P1/P1' positions Ala195/Val196, Val196/Ser197, and Thr198/Ile199, revealing a membrane proximal cleavage region in CD16. Mutation S197P effectively blocks CD16a and CD16b cleavage in cell-based assays. Mutant CD16a/S197P is resistant to cleavage when expressed in cells. The S197P mutation does not disrupt IgG binding by the receptor or its activation of NK92 cells by antibody-treated tumor cells
-
-
?
CD16b + H2O
?
show the reaction diagram
-
human IgG Fc receptor CD16, i.e. FcgammaRIII. CD16b plasma levels are significantly decreased in patients administered a selective inhibitor targeting the metalloproteases ADAM10 and ADAM17. Inhibition of ADAM17 significantly blocks the cleavage of CD16b following neutrophil activation and apoptosis
-
-
?
cell surface VEGF receptor Flt + H2O
?
show the reaction diagram
-
-
release of an N-terminal extracellular fragment which can antagonize the effects of vascular endothelial growth factor, substrate can be cleaved to release an N-terminal extracellular fragment. Overexpression of ADAM10, EC 3.4.24.81, and ADAM17 increase cleavage while knockdown of ADAM10 and ADAM17 reduce N-terminal cleavage
-
?
CSF-1 receptor + H2O
?
show the reaction diagram
-
TACE cleaves the receptor between residues Gln503 and Ser504. Replacement of fourteen residues at the end of the CSF-1 extracellular domain blocks TACE cleavage
-
-
?
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser(4O-(beta-D-Gal-(1->3)-alpha-D-GalNAc))-Ser-Lys(DABCYL) + H2O
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala + Val-Arg-Ser-Ser(4O-(beta-D-Gal-(1->3)-alpha-D-GalNAc))-Ser-Lys(DABCYL)
show the reaction diagram
-
-
-
-
?
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Lys(DABCYL) + H2O
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala + Val-Arg-Ser-Ser-Ser-Lys(DABCYL)
show the reaction diagram
-
-
-
-
?
interleukin-6 receptor + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is LPVQ357-/-DSSV, N-linked glycosylation sites are: Asn55, Asn93, Asn221, Asn350
-
-
?
PLAAAVFSS + H2O
PLAAA + VFSS
show the reaction diagram
-
mutant peptide derived from TNF-alpha, very poor substrate
-
-
?
PLAMAVMSS + H2O
PLAMA + VMSS
show the reaction diagram
-
mutant peptide derived from TNF-alpha, very poor substrate
-
-
?
PLAQAVRSS + H2O
PLAQA + VRSS
show the reaction diagram
-
peptide derived from TNF-alpha
-
-
?
Pro-BTC + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is CVVA31-/-DGNS, N-linked glycosylation site is Asn34
-
-
?
pro-EPR + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is DNPR59-/-VAQV, N-linked glycosylation site is Asn47
-
-
?
pro-HB-EGF + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is RKVR62-/-DLQE, O-linked glycosylation sites are Thr75 and Thr85
-
-
?
pro-TGFalpha + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is VAAA39-/-VVSH, N-linked glycosylation site is Asn25
-
-
?
pro-tumor necrosis factor alpha + H2O
?
show the reaction diagram
-
with and without a glycan moiety attached, glycosylation increases the enzyme activity. The cleavage site of TNFalpha by ADAM17 is only four residues away from a glycosylated residues, whereas glycosylation occurs 14 residues away from the TGFalpha cleavage site. Cleavage site for ADAM-17 is LAQA76-/-VRSS, O-linked glycosylation site is Ser80
-
-
?
proheparin-binding EGF-like growth factor + H2O
?
show the reaction diagram
-
-
cleavage occurs between residues RKVR62-DLQE. Substrate shows O-linked glycosylation 13 residues apart from scissile bond
-
?
proTNF-alpha + H2O
soluble TNF-alpha + H2O
show the reaction diagram
-
-
cleavage occurs between residues LAQA76-VRSS. Substrate shows O-linked glycosylation 4 residues apart from scissile bond
-
?
protransforming growth factor alpha + H2O
?
show the reaction diagram
-
-
cleavage occurs between residues AAA39-VVSH. Substrate shows N-linked glycosylation 14 residues apart from scissile bond
-
?
S80-glycosylated (EDANS)-ELAQAVRSSSRK-(DABCYL) + H2O
?
show the reaction diagram
-
TNF-alpha derived substrate
-
-
?
S80-glycosylated (EDANS)-EPLAQAVRSSSK-(DABCYL) + H2O
?
show the reaction diagram
-
TNF-alpha derived substrate
-
-
?
syndecan-1 + H2O
?
show the reaction diagram
-
both ADAM10 and ADAM17 contribute to SDC1 shedding
-
-
?
TGF-alpha + H2O
?
show the reaction diagram
-
ADAM17, but not related ADAM10, is required for amphiregulin, TGF-alpha, and TNFR1 shedding
-
-
?
TNF-alpha + H2O
?
show the reaction diagram
-
-
-
-
?
transferrin receptor protein 1 + H2O
?
show the reaction diagram
-
-
cleavage occurs between residues ECER100-LAGT. Substrate shows O-linked glycosylation 4 residues apart from scissile bond
-
?
TRP1 + H2O
?
show the reaction diagram
-
the cleavage site by ADAM17 is ECER100-/-LAGT, O-linked glycosylation sites are: Thr104, Asn251, Asn317, Asn727
-
-
?
tumor necrosis factor receptor 1 + H2O
?
show the reaction diagram
-
ADAM17, but not related ADAM10, is required for amphiregulin, TGF-alpha, and TNFR1 shedding
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-KSPLAQA-VRSSSRK(2,4-dinitrophenyl)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-Pro-Leu-Ala-Gln-Ala-Val-[N-3-[2,4-dinitrophenyl]-L-2,3-diaminopropionyl]-Arg-Ser-Ser-Ser-Arg-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-SPLAQAVRSSSRK-(2,4-dinitrophenyl)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)acetyl-Ser-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Lys(Dnp)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
26 kDa proTNF-alpha + H2O
17 kDa soluble TNF-alpha + ?
show the reaction diagram
-
-
-
-
?
4',5'-dimethoxyfluoresceinyl-SPLAQAVRSSSR-cys(4-(3-succinimid-1-yl)fluorescein)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
7-methoxycoumarin-4-(yl)acetyl-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl-Arg-NH2 + H2O
?
show the reaction diagram
-
an internally quenched peptide substrate is used
-
-
?
7-methoxycoumarin-4-yl-acetyl-Lys-Pro-Leu-Gly-Pro-Leu-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg + H2O
?
show the reaction diagram
-
-
-
-
?
75kDaTNFR2 + H2O
?
show the reaction diagram
-
-
-
-
?
acetyl-SPLAQAVRSSSR-COOH + H2O
acetyl-SPLAQA + VRSSSR-COOH
show the reaction diagram
-
-
-
-
?
Alzheimer's disease amyloid precursor protein + H2O
?
show the reaction diagram
amphiregulin + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid-protein precursor + H2O
?
show the reaction diagram
-
-
-
-
?
beta-amyloid precursor protein + H2O
?
show the reaction diagram
c-KLR + H2O
?
show the reaction diagram
-
-
-
-
?
CD30 + H2O
?
show the reaction diagram
cellular prion protein PrPc + H2O
?
show the reaction diagram
-
-
-
-
?
Dpa-SPLAQAVRSSSR-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
endothelial protein C receptor + H2O
?
show the reaction diagram
-
-
-
-
?
FcalphaR + H2O
?
show the reaction diagram
-
i.e. Fc receptor for immunoglobulin A
-
-
?
fractalkine + H2O
?
show the reaction diagram
GHR + H2O
?
show the reaction diagram
-
-
-
-
?
glycoprotein Ibalpha + H2O
?
show the reaction diagram
glycoprotein V + H2O
?
show the reaction diagram
-
-
-
-
?
heparin-binding EGF-like growth factor + H2O
?
show the reaction diagram
-
ADAM17 may be involved in heparin-binding EGF-like growth factor cleavage in response to injury
-
-
?
heparin-binding epidermal growth factor-like growth factor + H2O
?
show the reaction diagram
-
-
-
-
?
HER-4 Jma + H2O
?
show the reaction diagram
-
-
-
-
?
intercellular cell adhesion molecule-1 + H2O
?
show the reaction diagram
-
-
-
-
?
interleukin (IL)-1R-II + H2O
?
show the reaction diagram
interleukin-6-receptor + H2O
?
show the reaction diagram
-
-
-
-
?
KL-1 + H2O
?
show the reaction diagram
-
-
-
-
?
L-selectin + H2O
?
show the reaction diagram
LAQAVRSSSR + H2O
?
show the reaction diagram
-
fluorimetric assay for TACE, fluorogenic substrate, a 10-amino-acid peptide capped with an o-aminobenzoyl group on the N-terminal end and with a 3-(2,4-dinitrophenyl)-L-2,3-diaminopropionic amide group on the C-terminal end, enzymatic conversion of the substrate results in a fluorescence enhancement of 11fold
-
-
?
macrophage colony-stimulating factor receptor M-CSFR + H2O
?
show the reaction diagram
-
-
-
-
?
Mca-PLAQAV-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide-RSSSR-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
MHC class I-related chain + H2O
?
show the reaction diagram
-
i.e. transmembrane protein expressed in pathological conditions, ligands for the activating receptor NKG2D found on cytotoxic lymphocytes. The recruitment of both enzyme and substrate to detergent-resistant membrane microdomains is crucial for efficient proteolysis
-
-
?
NH2-LAQAVRSSSR-OH + H2O
?
show the reaction diagram
-
uncapped counterpart of the fluorogenic substrate
-
-
?
Notch 1 + H2O
?
show the reaction diagram
-
ADAM17 is required for Notch1 receptor proteolysis in NSCLC cells in vitro and in vivo
-
-
?
notch 1 receptor + H2O
?
show the reaction diagram
-
-
-
-
?
o-aminobenzoyl-LAQAFRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + FRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 22%
-
-
?
o-aminobenzoyl-LAQAIRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + IRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 66%
-
-
?
o-aminobenzoyl-LAQALRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + LRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 92%
-
-
?
o-aminobenzoyl-LAQAVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQA + VRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 90%
-
-
?
o-aminobenzoyl-LAQFVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQF + RSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 39%
-
-
?
o-aminobenzoyl-LAQGVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQG + VRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 11%
-
-
?
o-aminobenzoyl-LAQLVRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQL + VRSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 34%
-
-
?
o-aminobenzoyl-LAQVARSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide + H2O
o-aminobenzoyl-LAQVA + RSSSR-N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl amide
show the reaction diagram
-
enzymatic cleavage 19%
-
-
?
p55 TNFR1 + H2O
?
show the reaction diagram
p75 tumour necrosis factor receptor + H2O
?
show the reaction diagram
pN-collagen I substrate + H2O
?
show the reaction diagram
-
-
-
-
?
preadipocyte factor 1 + H2O
?
show the reaction diagram
pro amphiregulin + H2O
?
show the reaction diagram
-
TACE is capable of cleaving both N- and C-terminal sites in the pro-amphiregulin ectodomain
-
-
?
pro heparin-binding epidermal growth factor + H2O
?
show the reaction diagram
-
purified soluble TACE cleaves a single site in the juxtamembrane stalk of pro heparin-binding epidermal growth factor
-
-
?
protein C receptor + H2O
?
show the reaction diagram
-
-
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha
show the reaction diagram
proTNF-alpha + H2O
soluble TNF-alpha + 9000 Da membrane-bound fragment of TNF-alpha
show the reaction diagram
-
-
-
-
?
RANKL + ?
?
show the reaction diagram
-
-
-
-
?
receptor tyrosine kinase c-Kit + H2O
?
show the reaction diagram
soluble TNF + H2O
?
show the reaction diagram
-
-
-
-
?
soluble TNF receptor 1 + H2O
?
show the reaction diagram
-
-
-
-
?
soluble TNF receptor 2 + H2O
?
show the reaction diagram
-
-
-
-
?
soluble TNF-alpha receptor type 1 + H2O
?
show the reaction diagram
-
-
-
-
?
TNF-alpha + H2O
soluble TNF-alpha
show the reaction diagram
TRANCE + H2O
?
show the reaction diagram
-
-
-
-
?
transforming growth factor alpha + H2O
?
show the reaction diagram
transforming growth factor-alpha + H2O
?
show the reaction diagram
-
-
-
-
?
tumour necrosis factor receptor-1 + H2O
?
show the reaction diagram
-
-
-
-
?
tumour necrosis factor receptor-2 + H2O
?
show the reaction diagram
-
-
-
-
?
vascular cellular adhesion molecule-1 + H2O
?
show the reaction diagram
-
-
-
-
?
vasorin + H2O
soluble vasorin + ?
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
Alzheimer's disease amyloid precursor protein + H2O
?
show the reaction diagram
-
TACE is involved in shedding of Alzheimer's disease amyloid precursor protein
-
-
?
glycoprotein Ibalpha + H2O
?
show the reaction diagram
-
ADAM17 is the key enzyme mediating shedding of glycoprotein Ibalpha
-
-
?
Notch 1 + H2O
?
show the reaction diagram
-
ADAM17 is required for Notch1 receptor proteolysis in NSCLC cells in vitro and in vivo
-
-
?
preadipocyte factor 1 + H2O
?
show the reaction diagram
-
TACE is the major protease responsible for conversion of membrane-bound Pref-1 to the biologically active diffusible form
-
-
?
proTNF-alpha + H2O
soluble TNF-alpha + 9000 Da membrane-bound fragment of TNF-alpha
show the reaction diagram
-
-
-
-
?
receptor tyrosine kinase c-Kit + H2O
?
show the reaction diagram
-
ADAM-17 controls mast cell survival by regulating shedding and surface expression of c-Kit
-
-
?
TNF-alpha + H2O
soluble TNF-alpha
show the reaction diagram
vasorin + H2O
soluble vasorin + ?
show the reaction diagram
-
-
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Zn2+
-
active site zinc, metalloprotease
Zinc
-
pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity
additional information
-
metalloprotease
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(5S)-4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[(2S)-1-(2-[[(6S)-6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
-
90% inhibition at 0.04 mM
(5S)-5-(4-hydroxybenzyl)-1-[(2S)-1-(2-[[(6S)-6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]-4-[2-(tricyclo[3.3.1.13,7]dec-1-yl)ethyl]piperazine-2,3-dione
-
95% inhibition at 0.04 mM
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
-
-
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
-
-
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
-
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
-
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
-
-
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
-
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
-
-
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
-
-
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
-
-
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamanylpropyl]piperazine-2,3-dione
-
-
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
-
-
methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazin-1-ylcarbonyl)-5-azaspiro[2.5]octane-5-carboxylate
-
i.e. INCB7839, selective inhibitor of endopeptidases ADAM-10 and ADAM-17
(1R,2R)-2-(3-phenoxylphenyl)-2-trans-carbomethoxylcyclopropane hydroxamic acid
-
-
(1R,2R)-2-trans-carboisopropoxyl-2-[3-(2-methylquinolin-4-yl)methoxylphenyl]cyclopropane hydroxyamic acid
-
-
(1R,2R)-2-trans-N-benzylaminocarbonyl-2-[3-(2-methylquinolin-4-yl)methoxylphenyl]cyclopropane hydroxyamic acid
-
-
(1R,2R)-2-[3-(3,4-dichlorobenzyloxy)phenyl]-2-trans-carbomethoxylcyclopropane hydroxamic acid
-
-
(1R,2R)-N-hydroxy-2-[(4-methylpiperazin-1-yl)carbonyl]-2-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxamide
-
-
(1R,2R)-N1-benzyl-N2-hydroxy-N1-methyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N1-cyclohexyl-N2-hydroxy-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N2-hydroxy-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]-N1-phenylcyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N2-hydroxy-N1,N1-dimethyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2R)-N2-hydroxy-N1-methyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-(3-fluoro-4-[[2-(1-methyl-1H-pyrazol-5-yl)quinolin-4-yl]methoxy]benzyl)-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-(3-fluoro-4-[[2-(methylamino)quinolin-4-yl]methoxy]benzyl)-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[3-fluoro-4-[(2-morpholin-4-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[3-fluoro-4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N2-hydroxy-N1,N1-dimethylcyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[3-fluoro-4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[3-fluoro-4-[(2-pyridin-3-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[3-fluoro-4-[(2-pyrrolidin-1-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[4-(benzyloxy)benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[4-(but-2-yn-1-yloxy)benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-1-[4-[(2-ethylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N1-(piperidin-4-ylmethyl)cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-N1,N1-dimethyl-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-N1,N1-dimethyl-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1R,2S)-N2-hydroxy-N1-methyl-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
(1S,2R)-2-[[(3R)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl]-N-hydroxy-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
(1S,2R)-2-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl]-N-hydroxy-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
(1S,2R)-N-hydroxy-2-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
(1S,2R)-N-hydroxy-2-[[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl]-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
(1S,2R)-N-hydroxy-2-{4-[(2-imino-1,2-dihydroquinolin-4-yl)methoxy]benzyl}-2-(methoxycarbonyl)cyclopropanecarboximidic acid
-
-
(1S,2S)-2-((S)-cyano(4-((2-phenylquinolin-4-yl)methoxy)phenyl)methyl)-N-hydroxycyclopropanecarboxamide
-
-
(2R)-5-nitroguanyl-2-([(2R,3S)-2-(cyclohexylmethyl)-3-cyclopropyl-3-[formyl(hydroxy)amino]propanoyl]-amino)-N-(1,3-thiazol-2-yl)pentanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[(4-methylcyclohexyl)-methyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[(5-methyl-2-thienyl)methyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-(2-pyridylsulfonyl)guanyl-1-[(1,3-thiazol-2-ylamino)-carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutyl-4-methylpentanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl-(hydroxy)amino]-2-isobutyl-4-methylpentanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl-(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-methanesulfonylguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-6,6,6-trifluoro-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-(cyclohexylmethyl)-3-[formyl(hydroxy)amino]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-(cyclohexylmethyl)-6,6,6-trifluoro-3-[formyl(hydroxy)amino]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-2-[(1S)-1-[formyl(hydroxy)amino]-2-phenylethyl]-4-methylpentanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-[5-methyl-2-thienylmethyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]hexanamide
-
-
(2R,3S)-N-[(1S)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-4-methyl-2-[(4-methylcyclohexyl)methyl]pentanamide
-
-
(2R,3S)-N-[(1S,2R)-4-nitroguanyl-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl]-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2R,3S)-N-{(1R)-4-nitroguanyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butyl}-3-[formyl(hydroxy)amino]-2-isobutylhexanamide
-
-
(2S)-2-amino-5-({(E)-amino[(methylsulfonyl)imino]-methyl}amino)-N-(1,3-thiazol-2-yl)pentanamide hydrochloride
-
-
(2S)-2-[(tert-butoxycarbonyl)amino]-5-({(Z)-(methyl-sulfanyl)[(methylsulfonyl)imino]methyl}amino)pentanoic acid
-
-
(2S,3R)-2-[(tert-butoxycarbonyl)amino]-5-{[imino(2-oxido-2-oxohydrazino)methyl]amino}-3-methylpentanoic acid (3R) Nalpha-boc-Ngamma-nitro-3-methyl L-arginine
-
-
(2S,3R)-2-{[(benzyloxy)carbonyl]amino}-3-methyl-5-({(Z)-(methylsulfanyl)[(methylsulfonyl)imino]methyl}-amino)pentanoic acid
-
-
(2S,3R)-5-methanesulfonylguanyl-2-[((2R)-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-4-methylpentanoyl)amino]-3-methyl-N-(1,3-thiazol-2-yl)pentanamide
-
-
(2S,3R)-5-nitroguanyl-2-[((2R)-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-4-methylpentanoyl)amino]-3-methyl-N-(1,3-thiazol-2-yl)pentanamide
-
-
(3S)-4-[[4-(but-2-ynylamino)phenyl]sulfonyl]-N-hydroxy-2,2-dimethylthio-morpholine-3-carboxamide
-
-
(4-bromobut-2-enyloxymethyl)benzene
-
-
(4-methoxyphenyl)acetic acid 4-benzyloxybut-2-enyl ester
-
-
(5R)-5-(2',4'-difluorobiphenyl-4-yl)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-(4'-chlorobiphenyl-4-yl)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[2'-(1-methyl-1H-tetrazol-5-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4'-(trifluoromethyl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(quinolin-6-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[3'-(2-methyl-1,3-thiazol-4-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4'-(1H-pyrazol-3-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1,3-thiazol-2-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-methyl-2H-indazol-6-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-methylpyridin-4-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(3-phenyl-1,2-oxazol-5-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(4-methyl-2,5-dioxoimidazolidin-4-yl)phenyl]imidazolidine-2,4-dione (non-preferred name)
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrazin-2-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-2-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-4-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrimidin-5-yl)phenyl]imidazolidine-2,4-dione
-
-
(5R)-5-[4-(2-aminopyridin-4-yl)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5R)-5-[4-(5-chloro-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
(5S)-5-(4-fluorophenyl)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
1,10-phenanthroline
-
-
1-(1,3-benzoxazol-2-yl)-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
-
-
1-(1H-benzimidazol-2-yl)-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
-
-
1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-4-carboxamide
-
-
1-(2,2-dimethylpropyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-(butylsulfonyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-but-2-yn-1-yl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
1-ethylpropyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
1-methyl-2-morpholin-4-ylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
1-methylethyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxylate
-
-
1-methylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
1-[(4-acetylpiperazin-1-yl)sulfonyl]-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
-
-
2(R)-benzyloxymethyl-N-(2,2-dimethyl-1(S)-methyl-carbamoylpropyl)-3-(S)-(4-methoxyphenyl)succinamic acid
-
-
2-(3-benzyloxyphenyl)-2-trans-carbomethoxylcyclopropane hydroxyamic acid
-
-
2-(6-methyl-2-oxo-2H-chromen-3-ylmethyl)-pent-4-enoic acid hydroxyamide
-
-
2-(N-benzoxycarbonyl)aminoethyl-N-(4-hydroxyamino-4-oxo-2-(isopropylthio)butanoyl)-L-3-(2'-naphthyl)-L-alanyl amide
-
peptidomimetic inhibitor, 54.5% inhibition in in vitro lipopolysaccharide cytotoxicity tests, inhibitory activity in vivo by measuring the expression of mTNFalpha
2-(N-benzoxycarbonyl)aminoethyl-N-(4-hydroxyamino-4-oxo-2-(isopropylthio)butanoyl)-L-3-phenylalanyl-L-alanyl amide
-
peptidomimetic inhibitor, 27.3% inhibition in in vitro lipopolysaccharide cytotoxicity tests, molecular docking studies
2-(N-benzoxycarbonyl)aminoethyl-N-(4-hydroxyamino-4-oxo-2-(phenylthio)butanoyl)-L-3-phenylalanyl-L-alanyl amide
-
peptidomimetic inhibitor, 54.5% inhibition in in vitro lipopolysaccharide cytotoxicity tests
2-benzyl-N-hydroxy-3-(6-methyl-2-oxo-2H-chromen-3-yl)-propionamide
-
-
2-morpholin-4-ylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
2-[3-(2-methylquinolin-4-yl)methoxylphenyl]-2-trans-carboxamidocyclopropane hydroxyamic acid
-
-
2-[3-(2-methylquinolin-4-yl)methoxyphenyl]-2-trans-carbomethoxylcyclopropane hydroxyamic acid
-
-
3(R)-benzyloxymethyl-2-(S)-(4-methoxyphenyl)pent-4-enoic acid
-
-
3(R)-benzyloxymethyl-2-(S)-(4-methoxyphenyl)pent-4-enoic acid (2,2-dimethyl-1-(S)-methylcarbamoylpropyl)amide
-
-
3-(6-bromo-2-oxo-2H-chromen-3-yl)-N-hydroxy-propanamide
-
-
3-(6-chloro-2-oxo-2H-chromen-3-yl)-N-hydroxy-propanamide
-
-
3-(6-tert-butyl-2-oxo-2H-chromen-3-yl)-N-hydroxypropanamide
-
-
3-([[4-(1,3-dihydrofuro[3,4-b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-([[4-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-([[4-(2,3-dihydrofuro[2,3-b]quinolin-4-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(2,3-dimethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(2-cyclopropylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(2-ethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[([4-[(3-ethyl-2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
3-[4-[2-(hydroxyamino)-2-oxoethyl]-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidin-1-yl]propanoic acid
-
-
3-[[(4-[[2-(dimethylamino)quinolin-4-yl]methyl]phenyl)carbonyl]amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
-
-
4'-[(4R)-4-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2,5-dioxoimidazolidin-4-yl]biphenyl-4-carboxamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(2-methyl-benzoyl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(2-methyl-butyryl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(propane-2-sulfonyl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-isobutyryl-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-pyridin-4-ylmethyl-piperidine-4-carboxylic acid hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-piperidine-1,4-dicarboxylic acid 1-diethylamide 4-hydroxyamide
-
-
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-piperidine-4-carboxylic acid hydroxyamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-(dimethylsulfamoyl)-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(2,5-dichlorothiophen-3-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(2,5-dimethyl-1,3-thiazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dichloropyridin-4-yl)carbonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dichloropyridin-4-yl)methyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(5-chlorothiophen-2-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(morpholin-4-ylsulfonyl)piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(piperidin-1-ylsulfonyl)piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(pyrrolidin-1-ylsulfonyl)piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-pyridin-2-ylpiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-pyridin-4-ylpiperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[(2-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl]piperidine-4-carboxamide
-
-
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]sulfonyl]piperidine-4-carboxamide
-
-
4-[([4-[(1,1-dimethylbut-2-yn-1-yl)oxy]phenyl]sulfonyl)methyl]-N-hydroxy-1-(isopropylsulfonyl)piperidine-4-carboxamide
-
-
4-[2-(hydroxyamino)-2-oxoethyl]-N,N-dimethyl-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-1-carboxamide
-
-
4-[4-(4-hydroxy-but-2-ynylamino)-benzenesulfonylmethyl]-4-hydroxycarbamoyl-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thiomorpholinecarboxamide
-
IC50: 0.009 mM
5-[(5-methoxy-3-oxo-1,3-dihydro-2H-indazol-2-yl)methyl]-5-phenylimidazolidine-2,4-dione
-
-
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-(2-phenoxyphenyl)imidazolidine-2,4-dione
-
-
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-(3-phenoxyphenyl)imidazolidine-2,4-dione
-
-
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-oxopyrrolidin-1-yl)phenyl]imidazolidine-2,4-dione
-
-
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(morpholin-4-yl)phenyl]imidazolidine-2,4-dione
-
-
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-4-yloxy)phenyl]imidazolidine-2,4-dione
-
-
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrrolidin-1-ylcarbonyl)phenyl]imidazolidine-2,4-dione
-
-
5-[4-(cyclopentyloxy)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
5-[4-(isoquinolin-7-yloxy)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
-
APMA
-
inhibits TACE completely
BB 1101
-
-
BB 1433
-
-
BB 16
-
-
BB 2516
-
-
BB3103
-
-
-
benzyl (1S,2R)-4-({(E)-amino[(methylsulfonyl)imino]-methyl}amino)-2-methyl-1-[(1,3-thiazol-2-ylamino)carbonyl]butylcarbamate
-
-
BMS-561392
-
-
CGS 27023
-
-
CT 572
-
-
-
cyclohexyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
cyclohexylmethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
cyclopentyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
cyclopropyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
dithiothreitol
-
-
EGTA
-
1 mM, treatment of cells dramatically inhibits shedding of shedding of FcalphaR, i.e. Fc receptor for immunoglobulin A
EndoH
-
full-length TACE is sensitive to EndoH, mature TACE is resistant
-
ethyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxylate
-
-
ethyl (1R,2S)-1-[3-bromo-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-1-[3-chloro-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-1-[3-fluoro-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-1-[4-[(2-ethylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-phenoxybenzyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-[[2-(2-methylpropyl)quinolin-4-yl]methoxy]benzyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-[[2-(trifluoromethyl)quinolin-4-yl]methoxy]benzyl)cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-phenylpyridin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-pyridin-3-ylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
gelastatin hydroxamate
-
-
GI 129471
-
-
GM 6001
-
-
GM6001
GW 3333
GW1988
-
-
-
GW280264X
-
blocks ADAM10 and ADAM17 activity similarly
GW9471
IC-3
-
protects TACE from degradation by inhibiting either TACE itself or another metalloprotease
Immunex compound 3
-
-
JMV 390
-
-
KB-R7785
-
-
L-NG-(2-pyridylsulfonyl)arginine2-aminothiazole amide hydochloride
-
-
L-NG-nitroarginine 2-aminothiazole amide dihydrochloride
-
-
macrocyclic hydroxamic acid
-
-
-
methyl (1R,2R)-1-[3-(2-[3-[(1Z)-buta-1,3-dien-1-yl]phenyl]ethoxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-(benzyloxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-(but-2-yn-1-yloxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-(cyclohexylmethoxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-1-[3-[(4-chlorobenzyl)oxy]phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-methoxyphenyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-[[3-(trifluoromethyl)benzyl]oxy]phenyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-[[4-(trifluoromethyl)benzyl]oxy]phenyl)cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-methylphenoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-naphthalen-2-ylethoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-phenylethoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(4-methylphenoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(naphthalen-2-ylmethoxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(naphthalen-2-yloxy)phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(3-methoxybenzyl)oxy]phenyl]cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-(benzyloxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-(but-2-yn-1-yloxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-(cyclohexylmethoxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-[(2-chlorobenzyl)oxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-1-[4-[(3,4-dichlorobenzyl)oxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-(2-naphthalen-1-ylethoxy)benzyl]cyclopropanecarboxylate
-
-
methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-(2-naphthalen-2-ylethoxy)benzyl]cyclopropanecarboxylate
-
-
methyl 3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
methyl 4'-[(4R)-4-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2,5-dioxoimidazolidin-4-yl]biphenyl-4-carboxylate
-
-
MMP-1
-
-
-
MMP-2
-
-
-
N(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-alanine amide
-
IC50: about 0.11 mM
N-hydroxy-1-(2-methylpropyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-1-methyl-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-2-((6-methoxy-2H-chromen-3-yl)methyl)propanamide
-
-
N-hydroxy-2-(2-oxo-2H-chromen-3-yl)acetamide
-
-
N-hydroxy-2-methyl-3-(6-methyl-2-oxo-2H-chromen-3-yl)-propionamide
-
-
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide
-
-
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)propanamide
-
-
N-hydroxy-3-(6-methyl-2-oxo-2H-chromen-3-yl)propanamide
-
-
N-hydroxy-3-[([4-[(2-morpholin-4-ylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-2-carboxamide
-
-
N-hydroxy-3-[([4-[(3-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-2-carboxamide
-
-
N-hydroxy-3-[[(4-[[2-(trifluoromethyl)quinolin-4-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-2-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydrofuran-3-carboxamide
-
-
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-1-(methylsulfonyl)piperidine-4-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-1-propylpiperidine-4-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-4-carboxamide
-
-
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]tetrahydro-2H-pyran-4-carboxamide
-
-
N-[(4S,5S,7R)-2-[7-(1-benzylpiperidin-4-yl)]methylcarbamoyl-5-hydroxy-2-methyloct-4-yl]-N'-[(R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]isophthalamide
-
-
N-[1-(1,1-dimethylprop-2-yn-1-yl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(2,2-dimethylpropanoyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(2,2-dimethylpropyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(2-fluoroethyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(3,3-dimethylbutanoyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-(4,5-dihydro-1,3-thiazol-2-yl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-acetyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-ethyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-tert-butyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-[2-(ethylsulfonyl)ethyl]-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[1-[2-(hydroxyamino)-2-oxoethyl]cyclohexyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(2-methylpropanoyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(3-methylbutanoyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(methylsulfonyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-methylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-phenylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-propanoylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-propylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-[2-(methylsulfonyl)ethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydro-2H-pyran-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydro-2H-pyran-4-yl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
-
-
N-[DL-[2-(hydroxyamino-carbonyl)methyl]-4-methylpentanoyl]-L-3-(tert-butyl)glycyl-L-alanine,2-aminoethylamide
-
-
N-[[1-(hydroxycarbamoyl)cyclohexyl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
-
-
N1-benzyloxy-2(R)-benzyloxymethyl-N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-3(S)-(4-methoxyphenyl)-succinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(R)-(isobutyl)succinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(S)-(4-methoxyphenyl)succinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(S)-p-tolylsuccinamide
-
-
N4-(2,2-dimethyl-1(S)-methylcarbamoylpropyl)-N1-hydroxy-2(R)-hydroxymethyl-3(S)-phenylsuccinamide
-
-
NaCl
-
dramatic inhibitory effect on the activity of TACE
peptide hydroxamate
-
-
-
peptidomimetic hydroxamate
-
-
-
PKF242-484
-
-
pyridin-4-ylmethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
Ro 31-9790
-
-
Ro 32-7315
-
-
Ro32-7315
-
inhibitor specific for ADAM17, blocks shedding of CD30 antigen from cell membrane and a simultaneous release of soluble CD30
SC 903
-
-
-
SE 205
-
-
succinate
-
-
succinyl hydroxamate
-
-
sulfonamide hydroxamate
-
-
TACE-pro domain
-
pro domain is an inhibitor of the catalytic domain
-
TAPI-1
-
-
TAPI-2
tert-butyl (1S,2R)-4-{[imino(2-oxido-2-oxohydrazino)-methyl]amino}-2-methyl-1-[1,3-thiazol-2-ylaminocarbonyl]butylcarbamate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-3-methyl-4-pentenoate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-amino-3-methylpentanoate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-azido-3-methylpentanoate
-
-
tert-butyl (2S,3R)-2-{[(benzyloxy)carbonyl]amino}-5-hydroxy-3-methylpentanoate
-
-
tert-butyl 3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
-
-
tert-butyl 3-[4-[2-(hydroxyamino)-2-oxoethyl]-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidin-1-yl]propanoate
-
-
tert-butyl 4-(hydroxycarbamoyl)-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-1-carboxylate
-
-
tert-butyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
-
-
tert-butyl 4-([[4-(but-2-ynylamino)phenyl]sulfonyl]methyl)-4-[(hydroxyamino)-carbonyl]piperidine-1-carboxylate
-
-
tert-butyl 4-[([4-[but-2-ynyl(methyl)amino]phenyl]sulfonyl)methyl]-4-[(hydroxyamino)carbonyl]piperidine-1-carboxylate
-
-
tert-butyl(1S)-4-({(Z)-(methylsulfanyl)[(methylsulfonyl)-imino]methyl}amino)-1-[(1,3-thiazol-2-ylamino)carbonyl]butylcarbamate
-
-
TIMP-3
-
TMI-1
-
-
TMI-2
-
complete inhibition at 50 nM
TNF-alpha proteinase inhibitor
-
0.00005 mM
-
tumor necrosis factor-alpha protease inhibitor
-
-
-
tumor necrosis factor-alpha-converting enzyme pro domain
-
inhibition of the tumor necrosis factor-alpha-converting enzyme by its isolated pro domain, IC50: 70 nM
-
[((3R,4S)-4-{[(benzyloxy)carbonyl]}-4-carboxy-3-methylbutyl)amino](imino)methanaminium nitrate (3R) 3-methyl L-arginine nitric acid salt
-
-
[N-hydroxy-1-(isopropylsulfonyl)-4-[(4-[(1-methylbut-2-yn-1-yl)oxy]phenyl]sulfonyl)-methyl]piperidine-4-carboxamide
-
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
12-HPETE
-
i.e. 12-hydroperoxy-5Z,8Z,10E,14Z-eicosatetraenoic acid, a peroxide synthesized in the platelet lipoxygenase pathway, induces TACE-mediated receptor cleavage
anti-Ro/SSA autoantibody
-
i.e. antinuclear autoantibodies in the blood directed against Ro/Sjgren's syndrome ribonucleoprotein A antigen. Adalimumab appears to be significantly more efficacious than Etanercept in preventing TACE activation caused by anti-Ro/SSA autoantibodies
-
bortezomib
-
stimulates ADAM17-catalyzed shedding of CD30, blocks bortezomib-stimulated sCD30 release from L540 cells with an IC50 of approximately 230 nM
glucose oxidase
-
oxidative damage via glucose oxidase or hydrogen peroxide activates TACE and induces shedding of its targets, glycoprotein Ibalpha and glycoprotein V, in murine and human platelets. The TACE activation is independent of platelet activation. TACE activation induced by hydrogen peroxide is dependent on p38 mitogen-activated protein kinase signalling, whereas protein kinase C, phosphoinositide 3-kinase, and caspases are not involved. Inhibition of p38 cytoplasmic targets, phospholipase A2 and heat shock protein 27, does not prevent shedding, whereas blocking 12-lipoxygenase or Src kinase slightly inhibits TACE activation
-
granulocyte-macrophage colony-stimulating factor
-
granulocyte-macrophage colony-stimulating factor GM-CSF and interleukin-4 in combination potently up-regulate tumor necrosis factor-alpha coverting enzyme TACE and activity in monocytes, causing ectodomain shedding of M-CSF receptor
-
heparan sulfate
-
removal of cell surface heparan sulfate increases TACE activity and TACE-dependent formation of ErbB4 80 kDa intracellular domain
hydrogen peroxide
-
-
interleukin-4
-
granulocyte-macrophage colony-stimulating factor GM-CSF and interleukin-4 in combination potently up-regulate tumor necrosis factor-alpha coverting enzyme TACE and activity in monocytes, causing ectodomain shedding of M-CSF receptor
-
lipopolysaccharide
-
-
N-formyl-L-methionyl-phenylalanine
-
ADAM17 substrates undergo efficient turnover during extended neutrophil activation by N-formyl-L-methionyl-phenylalanine
phorbol 12-myristate-13-acetate
-
PMA
phorbol ester
phorbol-12-myristate 13-acetate
-
-
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0072 - 0.016
(EDANS)-ELAQAVRSSSRK-(DABCYL)
0.0034 - 0.012
(EDANS)-EPLAQAVRSSSK-(DABCYL)
0.003
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser(4O-(beta-D-Gal-(1->3)-alpha-D-GalNAc))-Ser-Lys(DABCYL)
-
pH 7.5, 22C
0.012
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Lys(DABCYL)
-
pH 7.5, 22C
0.0076 - 0.068
S80-glycosylated (EDANS)-ELAQAVRSSSRK-(DABCYL)
0.003 - 0.01
S80-glycosylated (EDANS)-EPLAQAVRSSSK-(DABCYL)
1.3
NH2-LAQAVRSSSR-OH
-
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.05 - 0.2
(EDANS)-ELAQAVRSSSRK-(DABCYL)
0.06 - 0.14
(EDANS)-EPLAQAVRSSSK-(DABCYL)
0.25
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser(4O-(beta-D-Gal-(1->3)-alpha-D-GalNAc))-Ser-Lys(DABCYL)
-
pH 7.5, 22C
0.14
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Lys(DABCYL)
-
pH 7.5, 22C
0.08 - 0.42
S80-glycosylated (EDANS)-ELAQAVRSSSRK-(DABCYL)
0.08 - 0.36
S80-glycosylated (EDANS)-EPLAQAVRSSSK-(DABCYL)
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
12 - 19
(EDANS)-EPLAQAVRSSSK-(DABCYL)
76
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser(4O-(beta-D-Gal-(1->3)-alpha-D-GalNAc))-Ser-Lys(DABCYL)
-
pH 7.5, 22C
12
Glu(EDANS)-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Lys(DABCYL)
-
pH 7.5, 22C
1.1 - 61
S80-glycosylated (EDANS)-ELAQAVRSSSRK-(DABCYL)
23 - 76
S80-glycosylated (EDANS)-EPLAQAVRSSSK-(DABCYL)
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0011
(1R,2R)-2-(3-phenoxylphenyl)-2-trans-carbomethoxylcyclopropane hydroxamic acid
-
-
0.000008
(1R,2R)-2-trans-carboisopropoxyl-2-[3-(2-methylquinolin-4-yl)methoxylphenyl]cyclopropane hydroxyamic acid
-
-
0.00014
(1R,2R)-2-trans-N-benzylaminocarbonyl-2-[3-(2-methylquinolin-4-yl)methoxylphenyl]cyclopropane hydroxyamic acid
-
-
0.000011
(1R,2R)-2-[3-(3,4-dichlorobenzyloxy)phenyl]-2-trans-carbomethoxylcyclopropane hydroxamic acid
-
-
0.005
(1R,2R)-N-hydroxy-2-[(4-methylpiperazin-1-yl)carbonyl]-2-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxamide
-
-
0.003
(1R,2R)-N1-benzyl-N2-hydroxy-N1-methyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
0.000009
(1R,2R)-N1-cyclohexyl-N2-hydroxy-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
0.000011
(1R,2R)-N2-hydroxy-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]-N1-phenylcyclopropane-1,2-dicarboxamide
-
-
0.0027
(1R,2R)-N2-hydroxy-N1,N1-dimethyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
0.0001
(1R,2R)-N2-hydroxy-N1-methyl-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropane-1,2-dicarboxamide
-
-
0.00000015
(1R,2S)-1-(3-fluoro-4-[[2-(1-methyl-1H-pyrazol-5-yl)quinolin-4-yl]methoxy]benzyl)-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
0.00000076
(1R,2S)-1-(3-fluoro-4-[[2-(methylamino)quinolin-4-yl]methoxy]benzyl)-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
0.00000021
(1R,2S)-1-[3-fluoro-4-[(2-morpholin-4-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
0.00000036
(1R,2S)-1-[3-fluoro-4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N2-hydroxy-N1,N1-dimethylcyclopropane-1,2-dicarboxamide
-
-
0.00000014
(1R,2S)-1-[3-fluoro-4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
0.00000014
(1R,2S)-1-[3-fluoro-4-[(2-pyridin-3-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
0.00000015
(1R,2S)-1-[3-fluoro-4-[(2-pyrrolidin-1-ylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
0.00036
(1R,2S)-1-[4-(benzyloxy)benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
0.00008
(1R,2S)-1-[4-(but-2-yn-1-yloxy)benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
0.000001
(1R,2S)-1-[4-[(2-ethylquinolin-4-yl)methoxy]benzyl]-N2-hydroxycyclopropane-1,2-dicarboxamide
-
-
0.000003
(1R,2S)-N2-hydroxy-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
0.00000063
(1R,2S)-N2-hydroxy-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]-N1-(piperidin-4-ylmethyl)cyclopropane-1,2-dicarboxamide
-
-
0.00000018
(1R,2S)-N2-hydroxy-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
0.000001
(1R,2S)-N2-hydroxy-N1,N1-dimethyl-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
0.00000028
(1R,2S)-N2-hydroxy-N1,N1-dimethyl-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
0.000014
(1R,2S)-N2-hydroxy-N1-methyl-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropane-1,2-dicarboxamide
-
-
0.00000038
(1S,2R)-2-[[(3R)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl]-N-hydroxy-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
0.00000054
(1S,2R)-2-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl]-N-hydroxy-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
0.0000003
(1S,2R)-N-hydroxy-2-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
0.00000025
(1S,2R)-N-hydroxy-2-[[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl]-2-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxamide
-
-
0.000012
(1S,2R)-N-hydroxy-2-{4-[(2-imino-1,2-dihydroquinolin-4-yl)methoxy]benzyl}-2-(methoxycarbonyl)cyclopropanecarboximidic acid
-
-
0.000004
(1S,2S)-2-((S)-cyano(4-((2-phenylquinolin-4-yl)methoxy)phenyl)methyl)-N-hydroxycyclopropanecarboxamide
-
-
0.000002
(5R)-5-(2',4'-difluorobiphenyl-4-yl)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000002
(5R)-5-(4'-chlorobiphenyl-4-yl)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.00001
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[2'-(1-methyl-1H-tetrazol-5-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000018
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4'-(trifluoromethyl)biphenyl-4-yl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000002
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000001
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000008
(5R)-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(quinolin-6-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000031
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[3'-(2-methyl-1,3-thiazol-4-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000002
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4'-(1H-pyrazol-3-yl)biphenyl-4-yl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000006
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1,3-thiazol-2-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000002
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000003
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000002
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-methyl-2H-indazol-6-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000005
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-methylpyridin-4-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000028
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(3-phenyl-1,2-oxazol-5-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000026
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(4-methyl-2,5-dioxoimidazolidin-4-yl)phenyl]imidazolidine-2,4-dione (non-preferred name)
-
pH and temperature not specified in the publication
0.0000012
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrazin-2-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000005
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-2-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000008
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-3-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000006
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-4-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000009
(5R)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrimidin-5-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000014
(5R)-5-[4-(2-aminopyridin-4-yl)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000005
(5R)-5-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000001
(5R)-5-[4-(5-chloro-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.0000008
(5S)-5-(4-fluorophenyl)-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000005
1-methylethyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxylate
-
-
0.00019
2-(3-benzyloxyphenyl)-2-trans-carbomethoxylcyclopropane hydroxyamic acid
-
-
0.0007
2-[3-(2-methylquinolin-4-yl)methoxylphenyl]-2-trans-carboxamidocyclopropane hydroxyamic acid
-
-
0.000008
2-[3-(2-methylquinolin-4-yl)methoxyphenyl]-2-trans-carbomethoxylcyclopropane hydroxyamic acid
-
-
0.000003
4'-[(4R)-4-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2,5-dioxoimidazolidin-4-yl]biphenyl-4-carboxamide
-
pH and temperature not specified in the publication
0.000006
5-[(5-methoxy-3-oxo-1,3-dihydro-2H-indazol-2-yl)methyl]-5-phenylimidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000029
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-(2-phenoxyphenyl)imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000027
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-(3-phenoxyphenyl)imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000008
5-[(6-fluoro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(2-oxopyrrolidin-1-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000006
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(morpholin-4-yl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000007
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyridin-4-yloxy)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000006
5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[4-(pyrrolidin-1-ylcarbonyl)phenyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000003
5-[4-(cyclopentyloxy)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000008
5-[4-(isoquinolin-7-yloxy)phenyl]-5-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]imidazolidine-2,4-dione
-
pH and temperature not specified in the publication
0.000016
ethyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(2-methylquinolin-4-yl)methoxy]phenyl]cyclopropanecarboxylate
-
-
0.000381
ethyl (1R,2S)-1-[3-bromo-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.000158
ethyl (1R,2S)-1-[3-chloro-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.000005
ethyl (1R,2S)-1-[3-fluoro-4-[(2-methylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.000002
ethyl (1R,2S)-1-[4-[(2-ethylquinolin-4-yl)methoxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.0031
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-phenoxybenzyl)cyclopropanecarboxylate
-
-
0.000018
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-[[2-(2-methylpropyl)quinolin-4-yl]methoxy]benzyl)cyclopropanecarboxylate
-
-
0.000003
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-(4-[[2-(trifluoromethyl)quinolin-4-yl]methoxy]benzyl)cyclopropanecarboxylate
-
-
0.000006
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-methylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
0.000037
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-phenylpyridin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
0.000012
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-phenylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
0.000022
ethyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-[(2-pyridin-3-ylquinolin-4-yl)methoxy]benzyl]cyclopropanecarboxylate
-
-
0.00005
methyl (1R,2R)-1-[3-(2-[3-[(1Z)-buta-1,3-dien-1-yl]phenyl]ethoxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.0012
methyl (1R,2R)-1-[3-(benzyloxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.0016
methyl (1R,2R)-1-[3-(but-2-yn-1-yloxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.0009
methyl (1R,2R)-1-[3-(cyclohexylmethoxy)phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.00005
methyl (1R,2R)-1-[3-[(4-chlorobenzyl)oxy]phenyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.003
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-methoxyphenyl)cyclopropanecarboxylate
-
-
0.00007
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-[[3-(trifluoromethyl)benzyl]oxy]phenyl)cyclopropanecarboxylate
-
-
0.000018
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-(3-[[4-(trifluoromethyl)benzyl]oxy]phenyl)cyclopropanecarboxylate
-
-
0.00024
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-methylphenoxy)phenyl]cyclopropanecarboxylate
-
-
0.00006
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-naphthalen-2-ylethoxy)phenyl]cyclopropanecarboxylate
-
-
0.00029
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(2-phenylethoxy)phenyl]cyclopropanecarboxylate
-
-
0.00014
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(4-methylphenoxy)phenyl]cyclopropanecarboxylate
-
-
0.003
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(naphthalen-2-ylmethoxy)phenyl]cyclopropanecarboxylate
-
-
0.00007
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-(naphthalen-2-yloxy)phenyl]cyclopropanecarboxylate
-
-
0.00011
methyl (1R,2R)-2-(hydroxycarbamoyl)-1-[3-[(3-methoxybenzyl)oxy]phenyl]cyclopropanecarboxylate
-
-
0.0008
methyl (1R,2S)-1-[4-(benzyloxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.00042
methyl (1R,2S)-1-[4-(but-2-yn-1-yloxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.026
methyl (1R,2S)-1-[4-(cyclohexylmethoxy)benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.00026
methyl (1R,2S)-1-[4-[(2-chlorobenzyl)oxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.00013
methyl (1R,2S)-1-[4-[(3,4-dichlorobenzyl)oxy]benzyl]-2-(hydroxycarbamoyl)cyclopropanecarboxylate
-
-
0.1
methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-(2-naphthalen-1-ylethoxy)benzyl]cyclopropanecarboxylate
-
-
0.1
methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[4-(2-naphthalen-2-ylethoxy)benzyl]cyclopropanecarboxylate
-
-
0.000009
methyl 4'-[(4R)-4-[(6-methoxy-1-oxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2,5-dioxoimidazolidin-4-yl]biphenyl-4-carboxylate
-
pH and temperature not specified in the publication
0.00008
N-[(4S,5S,7R)-2-[7-(1-benzylpiperidin-4-yl)]methylcarbamoyl-5-hydroxy-2-methyloct-4-yl]-N'-[(R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]isophthalamide
-
-
5
NaCl
-
-
additional information
additional information
-
inhibition kinetics, overview
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.05 - 0.06
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
0.051 - 0.058
1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)-4-[3-adamantylpropyl]piperazine-2,3-dione
0.031 - 0.045
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
0.054 - 0.056
4-(2-butylbenzyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
0.05 - 0.059
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
0.00536 - 0.057
4-(2-butylbenzyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
0.017 - 0.032
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
0.051 - 0.056
4-(cyclopentylmethyl)-1-[1-[2-[(2,3-dioxo-6-propylpiperazin-1-yl)methyl]pyrrolidin-1-yl]-3-(naphthalen-2-yl)propan-2-yl]-5-(4-hydroxybenzyl)piperazine-2,3-dione
0.034 - 0.042
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]piperazine-2,3-dione
0.00432 - 0.09
4-(cyclopentylmethyl)-5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]piperazine-2,3-dione
0.056 - 0.06
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
0.062
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(4-hydroxyphenyl)propan-2-yl]-4-[3-adamanylpropyl]piperazine-2,3-dione
Homo sapiens;
-
pH 7.5, 22C
0.061 - 0.095
5-(4-hydroxybenzyl)-1-[1-(2-[[6-(4-hydroxybenzyl)-2,3-dioxopiperazin-1-yl]methyl]pyrrolidin-1-yl)-3-(naphthalen-2-yl)propan-2-yl]-4-[3-adamantylpropyl]piperazine-2,3-dione
0.0000023
(3S)-4-[[4-(but-2-ynylamino)phenyl]sulfonyl]-N-hydroxy-2,2-dimethylthio-morpholine-3-carboxamide
Homo sapiens;
-
-
0.0000011
1-(1,3-benzoxazol-2-yl)-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
Homo sapiens;
-
-
0.000001
1-(1H-benzimidazol-2-yl)-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
Homo sapiens;
-
IC50 above 0.000001 mM
0.0000015
1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens;
-
-
0.0000023
1-(2,2-dimethylpropanoyl)-N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-4-carboxamide
Homo sapiens;
-
-
0.0000016
1-(2,2-dimethylpropyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens;
-
-
0.0000011
1-(butylsulfonyl)-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens;
-
-
0.000001
1-but-2-yn-1-yl-N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens;
-
-
0.0000012
1-ethylpropyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens;
-
-
0.0000014
1-methyl-2-morpholin-4-ylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens;
-
-
0.0000015
1-methylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens;
-
-
0.0000015
1-[(4-acetylpiperazin-1-yl)sulfonyl]-4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxypiperidine-4-carboxamide
Homo sapiens;
-
-
0.00003
2-(6-methyl-2-oxo-2H-chromen-3-ylmethyl)-pent-4-enoic acid hydroxyamide
Homo sapiens;
-
at 25C
0.000005
2-benzyl-N-hydroxy-3-(6-methyl-2-oxo-2H-chromen-3-yl)-propionamide
Homo sapiens;
-
at 25C
0.0000022
2-morpholin-4-ylethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens;
-
-
0.00084
3-(6-bromo-2-oxo-2H-chromen-3-yl)-N-hydroxy-propanamide
Homo sapiens;
-
at 25C
0.00055
3-(6-chloro-2-oxo-2H-chromen-3-yl)-N-hydroxy-propanamide
Homo sapiens;
-
at 25C
0.0124
3-(6-tert-butyl-2-oxo-2H-chromen-3-yl)-N-hydroxypropanamide
Homo sapiens;
-
at 25C
0.0000026
3-([[4-(1,3-dihydrofuro[3,4-b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens;
-
-
0.000001
3-([[4-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens;
-
-
0.0000013
3-([[4-(2,3-dihydrofuro[2,3-b]quinolin-4-ylmethyl)phenyl]carbonyl]amino)-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens;
-
-
0.0000012
3-[([4-[(2,3-dimethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens;
-
-
0.0000013
3-[([4-[(2-cyclopropylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens;
-
-
0.0000017
3-[([4-[(2-ethylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens;
-
-
0.0000078
3-[([4-[(3-ethyl-2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens;
-
-
0.0000032
3-[4-[2-(hydroxyamino)-2-oxoethyl]-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidin-1-yl]propanoic acid
Homo sapiens;
-
-
0.0000012
3-[[(4-[[2-(dimethylamino)quinolin-4-yl]methyl]phenyl)carbonyl]amino]-N-hydroxytetrahydro-2H-pyran-2-carboxamide
Homo sapiens;
-
-
0.0000025
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(2-methyl-benzoyl)-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens;
-
-
0.0000035
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(2-methyl-butyryl)-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens;
-
-
0.000002
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-(propane-2-sulfonyl)-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens;
-
-
0.0000023
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-isobutyryl-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens;
-
-
0.0000064
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-1-pyridin-4-ylmethyl-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens;
-
-
0.000001
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-piperidine-1,4-dicarboxylic acid 1-diethylamide 4-hydroxyamide
Homo sapiens;
-
IC50 below 0.000001 mM
0.000064
4-(4-but-2-ynylamino-benzenesulfonylmethyl)-piperidine-4-carboxylic acid hydroxyamide
Homo sapiens;
-
-
0.0000018
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-(dimethylsulfamoyl)-N-hydroxypiperidine-4-carboxamide
Homo sapiens;
-
-
0.000001
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(2,5-dichlorothiophen-3-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens;
-
IC50 below 0.000001 mM
0.000001
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(2,5-dimethyl-1,3-thiazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens;
-
IC50 below 0.000001 mM
0.0000017
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dichloropyridin-4-yl)carbonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens;
-
-
0.0000016
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dichloropyridin-4-yl)methyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens;
-
-
0.000001
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens;
-
IC50 below 0.000001 mM
0.0000022
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens;
-
-
0.000007
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-1-[(5-chlorothiophen-2-yl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
Homo sapiens;
-
-
0.000001
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(morpholin-4-ylsulfonyl)piperidine-4-carboxamide
Homo sapiens;
-
-
0.0000012
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(piperidin-1-ylsulfonyl)piperidine-4-carboxamide
Homo sapiens;
-
-
0.000001
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-(pyrrolidin-1-ylsulfonyl)piperidine-4-carboxamide
Homo sapiens;
-
-
0.00000133
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-pyridin-2-ylpiperidine-4-carboxamide
Homo sapiens;
-
-
0.0000056
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-pyridin-4-ylpiperidine-4-carboxamide
Homo sapiens;
-
-
0.000003
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[(2-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-4-carboxamide
Homo sapiens;
-
-
0.0000014
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl]piperidine-4-carboxamide
Homo sapiens;
-
-
0.0000015
4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-N-hydroxy-1-[[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]sulfonyl]piperidine-4-carboxamide
Homo sapiens;
-
-
0.000027
4-[([4-[(1,1-dimethylbut-2-yn-1-yl)oxy]phenyl]sulfonyl)methyl]-N-hydroxy-1-(isopropylsulfonyl)piperidine-4-carboxamide
Homo sapiens;
-
-
0.0000028
4-[2-(hydroxyamino)-2-oxoethyl]-N,N-dimethyl-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidine-1-carboxamide
Homo sapiens;
-
-
0.00001
4-[4-(4-hydroxy-but-2-ynylamino)-benzenesulfonylmethyl]-4-hydroxycarbamoyl-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens;
-
-
0.009
4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thiomorpholinecarboxamide
Homo sapiens;
-
IC50: 0.009 mM
0.0000028
cyclohexyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens;
-
-
0.000001
cyclohexylmethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens;
-
IC50 above 0.000001 mM
0.0000013
cyclopentyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens;
-
-
0.0000016
cyclopropyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens;
-
-
0.000028
gelastatin hydroxamate
Homo sapiens;
-
at 25C
0.000317
GM6001
Homo sapiens;
-
in 25 mM Tris-HCl buffer, pH 9, 0.0025 mM ZnCl2 and 0.005% (v/v) Brij-35, at 37C
0.00006 - 0.000065
JMV 390
0.0000033
methyl 3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
Homo sapiens;
-
-
0.11
N(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-alanine amide
Homo sapiens;
-
IC50: about 0.11 mM
0.0000016
N-hydroxy-1-(2-methylpropyl)-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens;
-
-
0.0000025
N-hydroxy-1-methyl-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens;
-
-
0.000036
N-hydroxy-2-((6-methoxy-2H-chromen-3-yl)methyl)propanamide
Homo sapiens;
-
at 25C
0.000175
N-hydroxy-2-(2-oxo-2H-chromen-3-yl)acetamide
Homo sapiens;
-
in 25 mM Tris-HCl buffer, pH 9.0, 0.0025 mM ZnCl2 and 0.005% (v/v) Brij-35, at 37C
0.000003
N-hydroxy-2-methyl-3-(6-methyl-2-oxo-2H-chromen-3-yl)-propionamide
Homo sapiens;
-
at 25C
0.00015
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide
Homo sapiens;
-
at 25C
0.00011
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)propanamide
Homo sapiens;
-
at 25C
0.00006
N-hydroxy-3-(6-methyl-2-oxo-2H-chromen-3-yl)propanamide
Homo sapiens;
-
at 25C
0.0000016
N-hydroxy-3-[([4-[(2-morpholin-4-ylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-2-carboxamide
Homo sapiens;
-
-
0.0000015
N-hydroxy-3-[([4-[(3-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-2-carboxamide
Homo sapiens;
-
-
0.0000022
N-hydroxy-3-[[(4-[[2-(trifluoromethyl)quinolin-4-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-2-carboxamide
Homo sapiens;
-
-
0.0000063
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens;
-
-
0.0000043
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide
Homo sapiens;
-
-
0.000001
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide
Homo sapiens;
-
-
0.000002
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)methyl]phenyl]carbonyl)amino]tetrahydrofuran-3-carboxamide
Homo sapiens;
-
-
0.0000035
N-hydroxy-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide
Homo sapiens;
-
-
0.0000019
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-1-(methylsulfonyl)piperidine-4-carboxamide
Homo sapiens;
-
-
0.000011
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]-1-propylpiperidine-4-carboxamide
Homo sapiens;
-
-
0.0000049
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-4-carboxamide
Homo sapiens;
-
-
0.0000023
N-hydroxy-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]tetrahydro-2H-pyran-4-carboxamide
Homo sapiens;
-
-
0.0000023
N-[1-(1,1-dimethylprop-2-yn-1-yl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000021
N-[1-(2,2-dimethylpropanoyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000026
N-[1-(2,2-dimethylpropyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000026
N-[1-(2-fluoroethyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000019
N-[1-(3,3-dimethylbutanoyl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000012
N-[1-(4,5-dihydro-1,3-thiazol-2-yl)-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000019
N-[1-acetyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000022
N-[1-ethyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000037
N-[1-tert-butyl-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000014
N-[1-[2-(ethylsulfonyl)ethyl]-4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000077
N-[1-[2-(hydroxyamino)-2-oxoethyl]cyclohexyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000018
N-[2-(hydroxycarbamoyl)cyclopentyl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
Homo sapiens;
-
-
0.0000012
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(2-methylpropanoyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000022
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(3-methylbutanoyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.000001
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-(methylsulfonyl)piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000031
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-methylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000019
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-phenylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000027
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-propanoylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.000002
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-propylpiperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000012
N-[4-[2-(hydroxyamino)-2-oxoethyl]-1-[2-(methylsulfonyl)ethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.0000014
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydro-2H-pyran-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.000097
N-[4-[2-(hydroxyamino)-2-oxoethyl]tetrahydro-2H-pyran-4-yl]-4-[(2-methylquinolin-4-yl)methyl]benzamide
Homo sapiens;
-
-
0.0000086
N-[[1-(hydroxycarbamoyl)cyclohexyl]methyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide
Homo sapiens;
-
-
0.000002
pyridin-4-ylmethyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens;
-
-
0.000041 - 0.000043
TAPI-2
0.0000013
tert-butyl 3-(hydroxycarbamoyl)-4-[([4-[(2-methylquinolin-4-yl)oxy]phenyl]carbonyl)amino]pyrrolidine-1-carboxylate
Homo sapiens;
-
-
0.0000019
tert-butyl 3-[4-[2-(hydroxyamino)-2-oxoethyl]-4-[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]piperidin-1-yl]propanoate
Homo sapiens;
-
-
0.0000024
tert-butyl 4-(hydroxycarbamoyl)-4-[[([4-[(2-methylquinolin-4-yl)methoxy]phenyl]carbonyl)amino]methyl]piperidine-1-carboxylate
Homo sapiens;
-
-
0.000001
tert-butyl 4-([[4-(but-2-yn-1-yloxy)phenyl]sulfonyl]methyl)-4-(hydroxycarbamoyl)piperidine-1-sulfinate
Homo sapiens;
-
IC50 above 0.000001 mM
0.0000016
tert-butyl 4-([[4-(but-2-ynylamino)phenyl]sulfonyl]methyl)-4-[(hydroxyamino)-carbonyl]piperidine-1-carboxylate
Homo sapiens;
-
-
0.0000033
tert-butyl 4-[([4-[but-2-ynyl(methyl)amino]phenyl]sulfonyl)methyl]-4 [(hydroxyamino)carbonyl]piperidine-1-carboxylate
Homo sapiens;
-
-
0.000008
TMI-1
Homo sapiens;
-
-
0.00007
tumor necrosis factor-alpha-converting enzyme pro domain
Homo sapiens;
-
inhibition of the tumor necrosis factor-alpha-converting enzyme by its isolated pro domain, IC50: 70 nM
-
0.000004
[N-hydroxy-1-(isopropylsulfonyl)-4-[(4-[(1-methylbut-2-yn-1-yl)oxy]phenyl]sulfonyl)-methyl]piperidine-4-carboxamide
Homo sapiens;
-
-
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.5
-
assay at
7.4
-
assay at
7.5
-
assay at
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
22
-
assay at room temperature
26
-
assay at
37
-
assay at
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
ADAM17 proteolytic targets, amphiregulin, transforming growth factor (TGF-alpha), syndecan-1 (SDC1), and tumor necrosis factor receptor 1 (TNFR1), are shed from HVECs in response to staphylococcal superantigen toxic shock syndrome toxin TSST-1. ADAM17, but not related ADAM10, is required for amphiregulin, TGF-alpha, and TNFR1 shedding. Both ADAM10 and ADAM17 contribute to SDC1 shedding and IL-8 production by HVECs in response to TSST-1
Manually annotated by BRENDA team
-
hepatic stellate cell line
Manually annotated by BRENDA team
-
adipose tissue
Manually annotated by BRENDA team
-
atherosclerotic plaque
Manually annotated by BRENDA team
-
TACE expression measured by immunohistochemical analysis is observed in 183 of 383 breast carcinomas. TACE expression is predominantly seen in tumors with high levels of released human epidermal growth factor-4 receptor intracellular domain (4ICD) and membranous human epidermal growth factor-4 receptor
Manually annotated by BRENDA team
-
metalloproteases ADAM-9, ADAM-15, and ADAM-17 are upregulated in advanced human atherosclerotic lesions in samples from carotid, aortic, and femoral territories compared to samples from internal thoracic artery free of atherosclerotic plaques. ADAM-9, ADAM-15, and ADAM-17-expressing cells colocalize with CD68-positive cells of monocytic origin in the atherosclerotic plaques, in the carotid territory, cells expressing the ADAMs codistribute also with smooth muscle cells
Manually annotated by BRENDA team
-
metalloproteases ADAM-9, ADAM-15, and ADAM-17 are upregulated in advanced human atherosclerotic lesions in samples from carotid, aortic, and femoral territories compared to samples from internal thoracic artery free of atherosclerotic plaques. ADAM-9, ADAM-15, and ADAM-17-expressing cells colocalize with CD68-positive cells of monocytic origin in the atherosclerotic plaques, in the femoral territory, cells expressing the ADAMs codistribute also with CD31-positive endothelial cells
Manually annotated by BRENDA team
-
ADAM-17, TIMP-3 and fractalkine are constitutively expressed
Manually annotated by BRENDA team
-
large cell anaplastic lymphoma cell line
Manually annotated by BRENDA team
-
CD30-positive Hodgkins lymphoma cell line
Manually annotated by BRENDA team
-
CD30-positive Hodgkins lymphoma cell line
Manually annotated by BRENDA team
-
sural nerve biopsies from Guillain-Barre syndrome patients. ADAM-17-expressing T cells can be localized primarily within the epi- and perineurium, whereas in control sections from patients with non-inflammatory neuropathies, no axpression can be depected. The enzyme may contribute to the pathogenesis of inflammatory demyelination of the peripheral nervous system
Manually annotated by BRENDA team
-
TACE expression measured by immunohistochemical analysis is observed in 39 of 217 ovarian carcinomas.TACE expression is predominantly seen in tumors with high levels of released human epidermal growth factor-4 receptor intracellular domain (4ICD) and membranous human epidermal growth factor-4 receptor
Manually annotated by BRENDA team
-
ADAM17/TACE mRNA is expressed in 3 of 10 normal pancreatic tissues, 6 of 8 samples from patients with chronic pancreatitis
Manually annotated by BRENDA team
-
ADAM17/TACE mRNA is expressed in 10 of 10 PDAC tissues. ADAM17/TACE mRNA expression is down-regulated in pancreatic cancer cells arrested in G2 -M phase. Critical involvement of ADAM17/TACE in the invasion behavior of pancreatic cancer cells
Manually annotated by BRENDA team
-
ADAM17/TACE mRNA is expressed in 10 of 10 PDAC tissues. ADAM17/TACE expression is a later event in progression of pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma
Manually annotated by BRENDA team
-
by analyzing villous samples representing different gestational ages, it is shown that TACE is continuously expressed in the placentas throughout gestation and that the levels of TACE are positively correlated with the levels of TGF-alpha, heparin-binding epidermal growth factor-like growth factor, and amphiregulin
Manually annotated by BRENDA team
-
Villous explant cultures or cytotrophoblastic cells are used. Preadministration of TACE inhibitor in villous explant cultures or transfection of cytotrophoblastic cells with TACE-specific small interference RNA decreases the shedding of heparin-binding epidermal growth factor-like growth factor and amphiregulin. Hypoxia (2% O2) causes an increase in the levels of TACE mRNA and protein in villous explants and primary cytotrophoblastic cells in vitro
Manually annotated by BRENDA team
-
TACE expression measured by immunohistochemical analysis is observed in 16 of 24 and 17 of 24 hormone-sensitive and hormone-insensitive prostate carcinomas. TACE expression is predominantly seen in tumors with high levels of released human epidermal growth factor-4 receptor intracellular domain (4ICD) and membranous human epidermal growth factor-4 receptor
Manually annotated by BRENDA team
-
CD30-negative acute lymphoblastic leukemia cell line
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
cytosolic tail of TACE precedes TACE activation
Manually annotated by BRENDA team
additional information
-
ADAM17 localizes to bifurcations in invading sprouts
-
Manually annotated by BRENDA team
PDB
SCOP
CATH
UNIPROT
ORGANISM
Homo sapiens;
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
16060
-
mature enzyme, estimated from amino acid sequence
80000
-
migrates as a 80 kDa protein under non-reducing conditions, immunoprecipitation
100000
-
100 kDa reduced form represents mature TACE lacking the prodomain, immunoprecipitation
120000
-
full length form of TACE migrates as a 120 kDa protein under reducing conditions, immunoprecipitation
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
glycoprotein
-
-
phosphoprotein
-
in wounded cells, ADAM17 is phosphorylated at serine residues in an extracellular signal-regulated kinases ERK1/2-dependent manner
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
docking of nine-residue peptide PLAQA-VRSS from proTNF-alpha. The peptide adopts an anti-parallel beta-sheet conformation against a nearby beta-sheet of the protein. In the complexmodel, the side-chains of residues P2 and P2' are largely exposed,and do not form highly favorable interactions
-
hanging drop vapour diffusion method with 15% polyethylene glycol 4000, 10% 2-propanol, 100 mM sodium citrate (pH 5.6)
-
molecular docking studies of inhibitor 2-(N-benzoxycarbonyl)aminoethyl-N-(4-hydroxyamino-4-oxo-2-(isopropylthio)butanoyl)-L-3-phenylalanyl-L-alanyl amide
-
TACE mutant V353G is crystallized with the respective inhibitors with a resolution of 1.7 A using the hanging drop method
-
X-ray crystal structure of the catalytic domain of TACE
-
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
extreme salt sensitivity
-
in absence of cell activators the enzyme is long-lived, with a half-life of more than 8h
-
surface-biotinylated TACE is stable in Jurkat cells with a half-life of at least 8h
-
TACE appears quite stable in untreated cells
-
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-70C, TACE stored in small aliquots prevents self-degradation
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
Ni-NTA column chromatography and Superdex-75 gel filtration
-
recombinant enzyme
-
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
cDNA clones coding for various segments of the TACE cytotail
-
cDNA encoding TACE, full-length human TACE, inefficiently expressed in insect cells, baculovirus particles in Sf9 cell line from Spodoptera frugiperda
-
cDNA fragment coding for the prodomain of human TACE, expressed and purified from a baculoviral expression system
-
cloned with retroviral expression plasmids
-
expressed in Trichoplusia Ni cells (High-5 cells9)
-
expressed using the baculovirus expression system; recombinantly expressed
-
expression in MCF-7 cell
-
human embryonic kidney 293 transfectants overexpressing TACE
-
PCR used or quantification of TACE-mRNA in fresh tissue
-
recombinantly expressed human TACE in plasmid transfected chinese hamster ovary cells
-
the catalytic domain of recombinant human TNF-converting enzyme (residues 215-477 with two mutations S266A and N452Q) and a His-tagged tai